Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
about
Updates on the management of diabetes in dialysis patientsEvaluation Series on Safety and Efficacy of Nutritional Supplements in Newly Diagnosed Hyperglycemia: A Placebo-Controlled, Randomized Study.Optimal therapy of type 2 diabetes: a controversial challengeNovel and emerging diabetes mellitus drug therapies for the type 2 diabetes patientA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Tofogliflozin: first global approval.Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.Effects of metformin and sitagliptin on glycolipid metabolism in type 2 diabetic rats on different dietsCardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed?Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.Personalizing Type 2 Diabetes Management: Use of a Patient-Centered Approach to Individualizing A1C Goals and Pharmacological Regimens.
P2860
Q27024782-91675D1C-0A20-4507-A2C3-6236115CFA39Q30386420-8E9C9E9B-E26D-420B-B253-55327E7B92FBQ33577712-53F5BB50-7E33-420A-AD59-4BE8514862D4Q33759570-2051D1DA-2B45-47F7-B99C-BF386D114FBEQ34161881-5D443963-8811-4224-9F4A-D0FB4D33B896Q34420901-764C2277-ECEF-42E1-9B28-EFB959F71852Q36131466-0529BCE2-B55C-45B3-A8BE-7AEC132D866CQ36179371-FA0032A0-E43F-413D-BEBF-0D5C60E4F874Q36845293-A437A28A-C14F-4C7B-B6F4-41F26CB7C8A4Q38184608-81B501C7-23CE-4FBF-83FF-13060F85434BQ38211881-A234564E-E130-4BA7-8D11-131231A43DF9Q38712728-4004C7C5-3212-4E91-B671-2DF6F879BFFBQ40236660-C4053B02-BF08-44CB-974C-3BAC2E61D99FQ42848424-C2729E6C-D4DB-4F72-A842-8B6916D5C816Q53482444-F3EE42DF-A6F1-42BC-965A-7ED34084A365
P2860
Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sodium-glucose cotransporter i ...... t of type 2 diabetes mellitus.
@en
type
label
Sodium-glucose cotransporter i ...... t of type 2 diabetes mellitus.
@en
prefLabel
Sodium-glucose cotransporter i ...... t of type 2 diabetes mellitus.
@en
P2860
P356
P1476
Sodium-glucose cotransporter i ...... t of type 2 diabetes mellitus.
@en
P2093
Philip Raskin
P2860
P304
P356
10.1002/DMRR.2403
P577
2013-07-01T00:00:00Z